rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-631-637rsp-3086Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSРазвитие универсальной алопеции на фоне терапии ингибиторами ФНО-α у больных анкилозирующим спондилитом: описание трех случаевThe development of universal alopecia during therapy with TNF-α inhibitors in patients with ankylosing spondylitis: description of three caseshttps://orcid.org/0000-0002-4626-0938КирееваМ. В.KireevaM. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-2246-686XАгафоноваЕ. М.AgafonovaE. M.

Агафонова Екатерина Михайловна

115522, Российская Федерация, Москва, Каширское шоссе, 34а

Ekaterina Agafonova

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-7353-4087ДимитреваА. Е.DimitrevaA. E.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-2486-8798СахароваК. В.SakharovaK. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-4505-0162КрасненкоС. О.KrasnenkoS. O.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-3195-5187ЭрдесШ. Ф.ErdesSh. F.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202131102021595631637Copyright © Киреева М.В., Агафонова Е.М., Димитрева А.Е., Сахарова К.В., Красненко С.О., Эрдес Ш.Ф., 20212021Киреева М.В., Агафонова Е.М., Димитрева А.Е., Сахарова К.В., Красненко С.О., Эрдес Ш.Ф.Kireeva M.V., Agafonova E.M., Dimitreva A.E., Sakharova K.V., Krasnenko S.O., Erdes S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3086

Очаговая, или гнездная, алопеция (ГА) – аутоиммунное многофакторное заболевание, характеризующееся усиленным выпадением волос в результате морфофункциональных изменений волосяных фолликулов. Выделяют четыре основных формы ГА, и наиболее тяжелой из них считается универсальная форма (Уф-ГА), при которой возможна полная потеря волосяного покрова по всему телу. Алопеция в практике врача-ревматолога может встречаться при некоторых системных заболеваниях соединительной ткани и назначении некоторых лекарственных препаратов, например, химиопрепаратов, ингибиторов фактора некроза опухоли α (иФНО-α). В статье представлены три случая развития Уф-ГА на фоне терапии иФНО-α. Обсуждаются возможные механизмы, а также роль провоспалительных цитокинов в развитии данного состояния.

Alopecia areata (АA) is an autoimmune multifactorial disease characterized by increased hair loss as a result of morphological and functional changes in hair follicles. АA is divided into four main forms, among which the most severe is the universal form (UA), in which complete hair loss is possible throughout the body. Alopecia in the practice of a rheumatologist can occur with some systemic diseases of the connective tissue, with the use of high doses of chemotherapy drugs and, more recently, with the use of inhibitors of tumor necrosis factors alpha (TNF-α). The article presents 3 clinical cases of the development of UA during therapy with TNF-α. Possible mechanisms are discussed, as well as the role of pro-inflammatory cytokines in the development of this condition.

очаговая алопецияуниверсальная алопецияанкилозирующий спондилитингибиторы ФНО-αalopecia areatauniversal alopeciaankylosing spondylitisTNF-α inhibitorsРабота выполнена в рамках научной темы, регистрационный № НИОКР АААА-А19-119021190147-6. «Патогенетические особенности и персонифицированная терапия анкилозирующего спондилита и псориатического артрита» и было одобрено локальным этическим комитетом ФГБНУ НИИР им В.А. Насоновой. Все пациенты подписали информированное согласие на участие в исследовании.ReferencesСамцова АВ, Барбинова ВВ (ред.). Дерматовенерология. М.:ГЭОТАР-Медиа;2016:432.Samtsov AV, Barbinov VV (eds). Dermatovenerology. Moscow:GEOTAR-Media;2016:432 (In Russ.).Корсунская ИМ, Пирузян АЛ, Панюкова СВ, Сорокина ИЛ. Опыт применения препаратов Иннеов и Кериум в терапии диффузного поредения волос и очаговой алопеции. Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2010;6:20-22.Korsunskaya IM, Piruzyan AL, Panyukova SV, Sorokina IL. Experience of drugs Inneov and Kerium using in the treatment of diffuse hair thinning and alopecia areata. Sovremennye problemy dermatovenerologii, immunologii i vrachebnoy kosmetologii. 2010;6:20-22 (In Russ.).Гнездная алопеция/ Клинические рекомендации Российского общества дерматовенерологов и косметологов. 2020.Alopecia areata. Clinical recommendations of the Russian Society of Dermatovenerologists and Cosmetologists. 2020 (In Russ.). URL: https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2019-2020/files/КР%20Гнездная%20алопеция%202020%20август.docx (Accessed: 20th August 2020).Чеботарёв ВВ, Асхаков МС (ред.). Дерматовенерология. М.:ГЭОТАР-Медиа;2016: 680.Chebotarev VV, Askhakov MS (eds). Dermatovenerology. Moscow:GEOTAR-Media;2016:680 (In Russ.).Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: A review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033-1048. doi: 10.1111/bjd.16808Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: A review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033-1048. doi: 10.1111/bjd.16808McElwee KJ, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP. Alopecia areata: An autoimmune disease? Exp Dermatol. 1999;8(5):371-379. doi: 10.1111/j.1600-0625.1999.tb00385.xMcElwee KJ, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP. Alopecia areata: An autoimmune disease? Exp Dermatol. 1999;8(5):371-379. doi: 10.1111/j.1600-0625.1999.tb00385.xGoh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: Associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20(9):1055-1060. doi: 10.1111/j.1468-3083.2006.01676.xGoh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: Associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20(9):1055-1060. doi: 10.1111/j.1468-3083.2006.01676.xShellow WV, Edwards JE, Koo JY. Profile of alopecia areata: A questionnaire analysis of patient and family. Int J Dermatol. 1992;31(3):186-189. doi: 10.1111/j.1365-4362.1992.tb03932.xShellow WV, Edwards JE, Koo JY. Profile of alopecia areata: A questionnaire analysis of patient and family. Int J Dermatol. 1992;31(3):186-189. doi: 10.1111/j.1365-4362.1992.tb03932.xAbe DT, Tashima LM, Basilio FM, Mulinari-Brenner F. Clinical experience with oral tofacitinib in a patient with alopecia areata universalis and rheumatoid arthritis. Int J Trichol. 2020;12:188-190.Abe DT, Tashima LM, Basilio FM, Mulinari-Brenner F. Clinical experience with oral tofacitinib in a patient with alopecia areata universalis and rheumatoid arthritis. Int J Trichol. 2020;12:188-190.Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177-190. doi: 10.1016/j.jaad.2009.10.032Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177-190. doi: 10.1016/j.jaad.2009.10.032Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1-12. doi: 10.1016/j.jaad.2017.04.1141Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1-12. doi: 10.1016/j.jaad.2017.04.1141Anzai A, Wang EHC, Lee EY, Aoki V, Christiano AM. Pathomechanisms of immune-mediated alopecia. Int Immunol. 2019;31(7):439-447. doi: 10.1093/intimm/dxz039Anzai A, Wang EHC, Lee EY, Aoki V, Christiano AM. Pathomechanisms of immune-mediated alopecia. Int Immunol. 2019;31(7):439-447. doi: 10.1093/intimm/dxz039Горланов ИА (ред.). Детская дерматовенерология. М.:ГЭОТАР-Медиа;2017:512.Gorlanov IA (ed.). Pediatric dermatovenerology. Moscow:GEOTAR-Media;2017:512 (In Russ.).Gorcey L, Gordon Spratt EA, Leger MC. Alopecia universalis successfully treated with adalimumab. JAMA Dermatol. 2014;150(12):1341-1344. doi: 10.1001/jamadermatol.2014.1544Gorcey L, Gordon Spratt EA, Leger MC. Alopecia universalis successfully treated with adalimumab. JAMA Dermatol. 2014;150(12):1341-1344. doi: 10.1001/jamadermatol.2014.1544Ostojic P, Pavlov-Dolijanovic S. Alopecia universalis unter Adalimumabtherapie bei einer Patientin mit rheumatoider ArthritisAlopecia universalis in a patient with rheumatoid arthritis developed during treatment with adalimumab. Z Rheumatol. 2018;77(5):412-415. doi: 10.1007/s00393-018-0464-zKandpal R. Alopecia universalis in a case of rheumatoid arthritis after treatment with etanercept. Int J Trichology. 2019;11(4):173-176. doi: 10.4103/ijt.ijt_22_19Kandpal R. Alopecia universalis in a case of rheumatoid arthritis after treatment with etanercept. Int J Trichology. 2019;11(4):173-176. doi: 10.4103/ijt.ijt_22_19Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84(11):979-984. doi: 10.4065/84.11.979Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84(11):979-984. doi: 10.4065/84.11.979Zhang JG, Oliver RF. Immunohistological study of the development of the cellular infiltrate in the pelage follicles of the DEBR model for alopecia areata. Br J Dermatol. 1994;130(4):405-414. doi: 10.1111/j.1365-2133.1994.tb03371.xZhang JG, Oliver RF. Immunohistological study of the development of the cellular infiltrate in the pelage follicles of the DEBR model for alopecia areata. Br J Dermatol. 1994;130(4):405-414. doi: 10.1111/j.1365-2133.1994.tb03371.xMcElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(–) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124(5):947-957. doi: 10.1111/j.0022-202X.2005.23692.xMcElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(–) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124(5):947-957. doi: 10.1111/j.0022-202X.2005.23692.xKasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-alpha in patients with alopecia areata. Indian J Dermatol. 2011;56(5):494-496. doi: 10.4103/0019-5154.87124Kasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-alpha in patients with alopecia areata. Indian J Dermatol. 2011;56(5):494-496. doi: 10.4103/0019-5154.87124Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A, et al. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. J Am Acad Dermatol. 2005;52(6):1082-1084. doi: 10.1016/j.jaad.2005.03.039Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A, et al. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. J Am Acad Dermatol. 2005;52(6):1082-1084. doi: 10.1016/j.jaad.2005.03.039Youssef R, Saad S, Hendrick S. Alopecia universalis and onychodystrophy during treatment with adalimumab. Proc (Bayl Univ Med Cent). 2020;33(4):596-597. doi: 10.1080/08998280.2020.1771140Youssef R, Saad S, Hendrick S. Alopecia universalis and onychodystrophy during treatment with adalimumab. Proc (Bayl Univ Med Cent). 2020;33(4):596-597. doi: 10.1080/08998280.2020.1771140Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, et al.; Groupe de Recherche sur Psoriasis de Société Française de, Dermatologie; Club Rhumatismes et Inflammation (CRI); Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study. J Am Acad Dermatol. 2014;70(6):1146-1149. doi: 10.1016/j.jaad.2014.03.005Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, et al.; Groupe de Recherche sur Psoriasis de Société Française de, Dermatologie; Club Rhumatismes et Inflammation (CRI); Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study. J Am Acad Dermatol. 2014;70(6):1146-1149. doi: 10.1016/j.jaad.2014.03.005Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: New insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004;140(8):1012. doi: 10.1001/archderm.140.8.1012-aEttefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: New insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004;140(8):1012. doi: 10.1001/archderm.140.8.1012-aFerran M, Calvet J, Almirall M, Pujol RM, Maymó J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature. J Eur Acad Dermatol Venereol. 2011;25(4):479-484. doi: 10.1111/j.1468-3083.2010.03770.xFerran M, Calvet J, Almirall M, Pujol RM, Maymó J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature. J Eur Acad Dermatol Venereol. 2011;25(4):479-484. doi: 10.1111/j.1468-3083.2010.03770.xNoda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336. doi: 10.1016/j.jaci.2014.11.015Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336. doi: 10.1016/j.jaci.2014.11.015Ganzetti G, Campanati A, Offidani A. Alopecia areata: A possible extraintestinal manifestation of Crohn’s disease. J Crohns Colitis. 2012;6(9):962-963. doi: 10.1016/j.crohns.2012.05.023Ganzetti G, Campanati A, Offidani A. Alopecia areata: A possible extraintestinal manifestation of Crohn’s disease. J Crohns Colitis. 2012;6(9):962-963. doi: 10.1016/j.crohns.2012.05.023Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102(9):3372-3377. doi: 10.1073/pnas.0408506102Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102(9):3372-3377. doi: 10.1073/pnas.0408506102Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol. 2010;90(2):183-185. doi: 10.2340/00015555-0777Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol. 2010;90(2):183-185. doi: 10.2340/00015555-0777Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005;97(15):1143-1153. doi: 10.1093/jnci/dji207Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005;97(15):1143-1153. doi: 10.1093/jnci/dji207Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043-1049. doi: 10.1038/nm.3645Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043-1049. doi: 10.1038/nm.3645Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017;76(1):22-28. doi: 10.1016/j.jaad.2016.09.007Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017;76(1):22-28. doi: 10.1016/j.jaad.2016.09.007

The authors declare that there are no conflicts of interest present.